ID
42
Cancer Name
Brainstem Glioma (Adult Non-Pediatric)
Main Grouping
Nervous System
Organ System
Brainstem
Cell Origin
Glial cells
Pathways Affected
Adult brainstem glioma involves a complex and heterogeneous molecular pathway landscape defined by the specific molecular subtype: H3K27-altered diffuse midline glioma shows epigenetic pathway dysregulation through PRC2/H3K27me3 loss, PI3K/AKT/mTOR activation, and PDGFRA/EGFR RTK signaling; IDH-mutant glioma involves oncometabolite 2-HG production driving CIMP epigenetic silencing and Wnt/PI3K pathway activation; IDH-wildtype high-grade brainstem glioblastoma shows EGFR amplification, PTEN loss, TERT promoter mutation, and extreme chromosomal instability.
The PI3K/AKT/mTOR pathway is constitutively activated in adult high-grade brainstem glioma through EGFR amplification (approximately 25 percent), PTEN deletion (approximately 20 percent), and PI3K catalytic subunit mutations, driving glioma cell proliferation, survival, invasion, and angiogenesis; curcumin markedly decreased phosphorylated AKT levels in GBM cell lines while significantly reducing cell viability with no simultaneous decrease in viability of healthy astrocytes (PMC5078657); quercetin inhibits PI3K/AKT and mTOR in glioma cell models.
The EGFR signaling pathway is amplified in approximately 25 percent of adult high-grade brainstem gliomas and in approximately 40 to 50 percent of all IDH-wildtype glioblastomas; EGFR amplification drives constitutive RAS/RAF/MEK/ERK and PI3K/AKT/mTOR proliferative signaling; EGCG inhibits EGFR kinase activity and downstream AKT in glioma models. The H3K27M/PRC2 epigenetic pathway is disrupted in approximately 20 to 30 percent of adult brainstem gliomas through H3K27M mutation inhibiting the EZH2 component of the PRC2 complex, causing global H3K27me3 reduction and transcriptional derepression of oncogenes; curcumin inhibits DNMT activity and EZH2 in glioma cells, and inhibits GLI nuclear translocation in the Hedgehog pathway relevant to glioma stem cell maintenance. The IDH/2-HG metabolic pathway is mutated in approximately 20 percent of adult brainstem gliomas; IDH1/2 mutations generate the oncometabolite 2-hydroxyglutarate (2-HG) which competitively inhibits alpha-ketoglutarate-dependent enzymes including TET2 DNA demethylases (driving CIMP) and KDM histone demethylases (sustaining H3K27me3 hypermethylation in a paradoxical reversal of H3K27M biology); curcumin inhibits IDO-kynurenine and related metabolic enzyme activity in glioma models. The NF-kB inflammatory pathway is constitutively activated in glioblastoma through EGFR, PDGFRA, and TNF-alpha/IL-6 cytokine signaling in the glioma tumor microenvironment; curcumin directly inhibits IKK-mediated NF-kB activation in U87 and U251 glioma cells, reducing BCL-2, BCL-XL, survivin, MMP-9, and VEGF expression (PMC5078657). The MAPK/ERK pathway is activated downstream of EGFR and PDGFRA RTK signaling in brainstem glioma, driving cell proliferation and survival; curcumin modulated MAPK, Ras, and TNF signaling pathways in U87 MG cells as confirmed by RNA-sequencing (PMC12113757). The Wnt/beta-catenin pathway is activated in a subset of glioma through APC and CTNNB1 mutations and Wnt ligand overexpression; curcumin suppressed Wnt/beta-catenin signaling in U87 MG glioblastoma cells as shown by transcriptomic analysis (PMC12113757). The JAK/STAT3 pathway is constitutively activated in glioblastoma through IL-6 and EGF stimulation; curcumin inhibited JAK1,2/STAT3 tyrosine-phosphorylation and STAT3 target genes including c-Myc, MMP-9, Snail, Twist, and Ki67 in glioma cell models (PMC7998496). The Hedgehog/GLI signaling pathway is active in glioblastoma stem cells; curcumin inhibited SHH/GLI signaling through downregulating Shh, Smo, PTCH, and GLI protein levels in U87 and T98G glioma cells, reducing cyclin D1 and Bcl-2 (PMC7998496). The TGF-beta/SMAD pathway is activated in high-grade glioma driving immunosuppression in the tumor microenvironment, EMT, and invasion of brainstem structures; curcumin modulated TGF-beta pathway signaling in glioblastoma cells (PMC5078657). The p53 tumor suppressor pathway is disrupted through TP53 mutations in approximately 40 to 60 percent of adult high-grade brainstem gliomas; curcumin upregulated p53 expression and activated CDKi p21 in U251 glioblastoma cells (PMC5078657). The VEGF angiogenesis pathway is driven by HIF-1alpha and NF-kB in the hypoxic brainstem tumor microenvironment; curcumin decreased VEGF, MMP, and bFGF expression in glioma models (PMC10886523). The methionine/SAM cycle pathway is directly relevant to IDH-mutant brainstem glioma through CIMP-associated promoter hypermethylation of tumor suppressor genes, and to H3K27M brainstem glioma through EZH2-mediated H3K27me3 reduction.
Description
Adult brainstem glioma (ABG) represents a distinct subset of gliomas arising within the brainstem structures — the pons, midbrain, and medulla oblongata — in patients 18 years of age and older. Brainstem gliomas collectively account for approximately 1 to 2 percent of all adult primary brain tumors and approximately 9 to 10 percent of all posterior fossa brain tumors in adults. Unlike pediatric diffuse intrinsic pontine glioma (DIPG), which is almost universally fatal with median overall survival of 9 to 11 months, adult brainstem gliomas encompass a heterogeneous spectrum of tumors with variable prognosis determined primarily by their WHO 2021 molecular classification rather than anatomical location alone. The 5-year overall survival for adult brainstem gliomas ranges widely from approximately 5 to 15 percent for IDH-wildtype high-grade tumors to approximately 50 to 70 percent or more for IDH-mutant low-grade or adult WHO grade 2 brainstem gliomas; tectal gliomas of the midbrain tectum carry a 10-year overall survival exceeding 80 percent due to their typically indolent, low-grade biology.
The molecular heterogeneity of adult brainstem gliomas is now recognized as defining the clinical course and prognosis. The WHO 2021 CNS tumor classification established that the H3K27M histone mutation, when present in a diffuse midline glioma of the brainstem, assigns WHO grade IV status regardless of histological features, reflecting the universally poor prognosis of this molecular subtype; H3K27M mutation causes global epigenetic dysregulation through inhibition of the EZH2 component of the PRC2 complex, reducing H3K27 trimethylation (H3K27me3) across the genome and allowing transcriptional derepression of proliferative oncogenes. IDH1 codon 132 and IDH2 codon 172 mutations, found in approximately 20 percent of adult brainstem gliomas, carry the most favorable prognosis and occur predominantly in younger adult patients with WHO grade 2 or 3 astrocytoma or oligodendroglioma histology; IDH mutations produce the oncometabolite 2-hydroxyglutarate (2-HG) which inhibits alpha-ketoglutarate-dependent enzymes including TET2 DNA demethylases and histone KDM demethylases, driving a CpG island methylator phenotype (CIMP-glioma).
EGFR amplification in approximately 25 percent of adult high-grade brainstem gliomas drives constitutive EGFR/RAS/PI3K/AKT/mTOR signaling; PTEN deletion in approximately 20 percent releases PI3K/AKT from PTEN's negative regulatory phosphatase control; TP53 mutations in approximately 40 to 60 percent eliminate DNA damage checkpoint function. Adult brainstem gliomas are treated through surgical biopsy for molecular characterization, focal radiotherapy, and systemic treatment guided by molecular profile; the blood-brain barrier (BBB) significantly limits delivery of systemically administered therapeutics to brainstem tumor cells.
Multiple plant phytochemicals have documented activity in glioma and glioblastoma cell line models sharing the same molecular drivers as adult brainstem glioma. A published review (PMC5078657) documented curcumin inducing G2/M cell cycle arrest, activating apoptotic pathways, inducing autophagy, disrupting PI3K/AKT, Wnt/beta-catenin, NF-kB, TGF-beta, JAK/STAT3, MAPK, and Hedgehog signaling pathways in U87 and U251 GBM cells, and inhibiting invasion. Quercetin, EGCG, and resveratrol also have documented anti-glioma activity in published cell line models.
Plant-Based Description
Whole-food plant-based dietary patterns provide nutrients and phytochemicals with documented activity relevant to adult brainstem glioma through direct glioma and glioblastoma cell line anti-proliferative activity in U87, U251, U138 MG, T98G, and CH235 cell lines that share the same EGFR, PI3K/AKT, p53, PTEN, NF-kB, STAT3, and Hedgehog pathway alterations found in adult brainstem glioma; PI3K/AKT/mTOR suppression with markedly decreased phosphorylated AKT levels in GBM cells; G2/M cell cycle arrest; apoptosis activation through caspase-3/Bcl-2/Bax counter-regulation; autophagy induction; NF-kB inhibition reducing BCL-2, BCL-XL, MMP-9, and VEGF; STAT3 inhibition reducing c-Myc, Ki-67, Snail, and Twist; Wnt/beta-catenin suppression; Hedgehog/GLI pathway inhibition; invasion suppression through MMP reduction; and DNMT inhibition relevant to IDH-mutant CIMP epigenetics. Curcumin inhibited U87 MG cell proliferation in a dose- and time-dependent manner, induced apoptosis, caused G2/M arrest, and modulated Wnt/beta-catenin, PI3K/AKT/mTOR, NF-kB, TGF-beta, MAPK, Ras, and TNF signaling pathways by RNA-sequencing (PMC12113757). A systematic review with meta-analysis (PMC10886523) confirmed curcumin significantly reduced tumor volume in animal GBM xenograft models. EGCG, quercetin, and resveratrol all have documented anti-glioma activity in published cell line models.
Plant Chemistry Detail
Curcumin from turmeric has the most comprehensively documented multi-pathway anti-glioma activity across multiple cell lines with in vivo validation directly relevant to the molecular drivers of adult brainstem glioma. A published review (PMC5078657) documenting curcumin in brain tumor cell models including U87 and U251 GBM cells: curcumin induced G2/M cell cycle arrest in U87 cells through DUSP-2 upregulation and inhibition of ERK and JNK phosphorylation; curcumin upregulated p53, CDKi p21, and ING4 tumor suppressor gene in U251 GBM cells; curcumin inhibited PI3K/AKT, with markedly decreased phosphorylated AKT levels in GBM cell lines while cell viability of healthy astrocytes was not simultaneously decreased, confirming glioma-selective AKT inhibitory activity; curcumin activated apoptotic pathways through Bax/Bcl-2 counter-regulation; curcumin induced autophagy in glioma cells; curcumin inhibited invasion through MMP-2, MMP-9, VEGF, and bFGF suppression; curcumin inhibited NF-kB, reducing BCL-2, BCL-XL, survivin, and MMP-9; all directly targeting the EGFR/PI3K/AKT/NF-kB axis constitutively activated through EGFR amplification (approximately 25 percent of adult high-grade brainstem gliomas) and PTEN deletion (approximately 20 percent).
A transcriptomic analysis by RNA sequencing in U87 MG glioblastoma cells (PMC12113757) documented 5036 differentially expressed genes in curcumin-treated cells, with pathway enrichment identifying 13 dysregulated cancer-associated pathways including MAPK, Ras, TGF-beta, Wnt, Cytokine, and TNF signaling; curcumin induced RUNX3 upregulation (RUNX3 is progressively inactivated through promoter hypermethylation in gliomas, directly relevant to IDH-mutant CIMP brainstem glioma), with RUNX3 re-expression suppressing migration through MMP-2 inhibition; curcumin-induced RUNX3 upregulation caused Bim-caspase-dependent apoptosis and G0/G1 cell cycle arrest.
Curcumin inhibited JAK1,2/STAT3 tyrosine-phosphorylation and STAT3 target genes c-Myc, MMP-9, Snail, Twist, and Ki67 in glioma cell models, with curcumin-treated intracranially implanted tumor-bearing mice showing 15 to 38 percent long-term tumor-free survival (PMC7998496). Curcumin inhibited SHH/GLI signaling in U87 and T98G glioma cells, inhibiting GLI nuclear translocation and downstream cyclin D1 and Bcl-2, relevant to glioma stem cell biology in both H3K27M and IDH-wildtype brainstem glioma (PMC7998496). A systematic review with meta-analysis (PMC10886523) confirmed curcumin significantly reduced tumor volume in GBM xenograft models. Quercetin from yellow onions and kale inhibits PI3K/AKT, mTOR, NF-kB, and STAT3 and induces G2/M arrest in glioma cell models. EGCG from green tea inhibits EGFR kinase, PI3K/AKT, and NF-kB in glioma models, directly targeting the EGFR amplification found in approximately 25 percent of adult high-grade brainstem gliomas. Resveratrol from grapes inhibits PI3K/AKT, NF-kB, Wnt/beta-catenin, and STAT3 in glioma models and activates AMPK. Sulforaphane from cruciferous vegetables inhibits HDAC and DNMT activity targeting CIMP-associated promoter hypermethylation in IDH-mutant brainstem glioma and activates Nrf2. Apigenin from parsley inhibits STAT3 and PI3K/AKT in glioma cell models and induces intrinsic apoptosis. Luteolin from celery and parsley inhibits EGFR, STAT3, and NF-kB in glioma models.
Nutritional Focus
Nutritional focus in adult brainstem glioma research is led by curcumin from turmeric with the most comprehensively documented multi-pathway anti-glioma activity published across multiple GBM cell lines sharing the identical EGFR, PI3K/AKT, p53, PTEN, NF-kB, STAT3, and Wnt/beta-catenin molecular drivers found in adult high-grade brainstem gliomas: a published review (PMC5078657) documenting curcumin inducing G2/M cell cycle arrest, activating apoptotic pathways, inducing autophagy, inhibiting PI3K/AKT (with markedly decreased phosphorylated AKT specifically in GBM cell lines without affecting healthy astrocytes), inhibiting NF-kB, TGF-beta, Wnt/beta-catenin, and invasion through MMP/VEGF/bFGF suppression in U87 and U251 glioma cell models; a transcriptomic analysis (PMC12113757) documenting 5036 differentially expressed genes in curcumin-treated U87 MG glioblastoma cells with pathway enrichment identifying MAPK, Ras, TGF-beta, Wnt, and TNF signaling dysregulation, RUNX3 upregulation (relevant to CIMP epigenetics in IDH-mutant brainstem glioma), and migration suppression through MMP-2 inhibition; curcumin inhibiting JAK/STAT3 with reduced c-Myc, MMP-9, Snail, Twist, Ki67 in glioma cells with 15 to 38 percent long-term tumor-free survival in intracranial xenograft models (PMC7998496); curcumin inhibiting Hedgehog/GLI signaling in U87 and T98G glioma cells reducing GLI1, cyclin D1, and Bcl-2 relevant to glioma stem cell biology; a systematic review with meta-analysis (PMC10886523) confirming curcumin significantly reduced tumor volume in GBM xenograft models; EGCG from green tea inhibiting EGFR kinase directly targeting the approximately 25 percent EGFR amplification in adult high-grade brainstem gliomas and inhibiting PI3K/AKT and NF-kB; quercetin from yellow onions inhibiting PI3K/AKT, STAT3, and NF-kB in glioma models; sulforaphane from cruciferous vegetables inhibiting HDAC and DNMT targeting IDH-mutant CIMP-associated tumor suppressor gene silencing and H3K27M-driven chromatin dysregulation in brainstem glioma; resveratrol inhibiting PI3K/AKT, NF-kB, Wnt/beta-catenin, and STAT3 in glioma models; and folate from leafy greens and legumes supporting SAM-cycle methionine chemistry relevant to IDH-mutant CIMP epigenetics in adult brainstem glioma.
Research Notes
Adult brainstem glioma epidemiology: approximately 1-2% of all adult primary brain tumors; approximately 9-10% of posterior fossa brain tumors in adults; biologically heterogeneous by WHO 2021 molecular classification; 5-year OS ranges from approximately 5-15% for IDH-wildtype high-grade to approximately 50-70%+ for IDH-mutant low-grade; tectal gliomas 10-year OS exceeding 80%. Integrated genomic brainstem glioma analysis (PMC7299931): largest comprehensive cohort encompassing all age groups and anatomic locations (medulla, pons, midbrain); whole genome sequencing, RNA sequencing, methylation analysis; adult brainstem gliomas show distinct molecular profiles from pediatric DIPG. Adult molecular alterations: H3K27M mutations ~20-30%; IDH1/2 mutations ~20% (better prognosis); EGFR amplification ~25% high-grade adult; PTEN deletion ~20%; TP53 mutations ~40-60% high-grade; TERT promoter mutations ~30-35%; MGMT methylation ~40%; ATRX mutations co-occurring with IDH and TP53.
Curcumin in GBM (PMC5078657): G2/M arrest; apoptosis; autophagy; PI3K/AKT inhibition (markedly decreased phosphorylated AKT in GBM lines, not healthy astrocytes); NF-kB inhibition; MMP/VEGF/bFGF invasion suppression; p53/p21 upregulation in U251; multiple pathway inhibition. RNA-sequencing U87 MG curcumin (PMC12113757): 5036 differentially expressed genes; 13 cancer pathways; RUNX3 upregulation; migration suppression. Curcumin STAT3 glioma (PMC7998496): JAK/STAT3 inhibition; c-Myc/MMP-9/Snail/Twist/Ki67 reduction; 15-38% long-term tumor-free survival in xenograft models.
Notes Visibility
show
Key Foods
Turmeric,Broccoli,Kale,Spinach,Brussels Sprouts,Cauliflower,Garlic,Yellow Onion,Carrot,Tomato,Beetroot,Blueberry,Pomegranate,Grape,Raspberry,Strawberry,Orange,Lemon,Soybeans,Edamame,Green Lentils,Black Beans,Chickpeas,Brown Rice,Quinoa,Oats,Wild Rice,Rye Berries,Sorghum,Walnut,Almond,Brazil Nut,Pumpkin Seeds,Flaxseed,Chia Seeds,Sesame Seeds,Hemp Seeds,Shiitake,Maitake,Cremini,Portobello,Lions Mane,Green Tea,Ginger,Black Pepper,Garlic Powder,Parsley,Rosemary,Oregano, Celery, Leek,Avocado,Artichoke,Radish,Tangerine, Red Onion
Linked Nutrients
vitamin-c,vitamin-e,vitamin-d3,vitamin-b9,vitamin-b6,vitamin-a,selenium,zinc,magnesium,calcium,potassium,iron,curcumin,quercetin,egcg,resveratrol,sulforaphane,apigenin,beta-carotene,anthocyanins,beta-glucans,dietary-fiber,plant-ala-omega3
